State Street(R) SPDR(R) S&P(R) Biotech ETF (XBI)

Key Metrics

TER 35.00% per year

Distribution policy Distributing

Fund size USD 7,434 M

Inception date January 31, 2006

Holdings 158

Fund currency USD

Fund domicile US

Provider SPDR

For full official fund details, factsheets, and holdings, visit ssga.com (opens in new tab).

Historical Return

Last updated: Jun 01, 2026

1 Year +68.3% +0.3% Div

3 Years (avg.) +17.1% +0.3% Div

5 Years (avg.) +1.6% +0.3% Div

Risk & Analysis Metrics

Last updated: Jun 01, 2026

Volatility

23.46% 1 Year

26.11% 3 Years

31.52% 5 Years

31.69% 10 Years

Max Drawdown

-9.72% 1 Year

-32.99% 3 Years

-54.71% 5 Years

-63.90% 10 Years

Sharpe Ratio

1.93 1 Year

0.54 3 Years

0.07 5 Years

0.29 10 Years

Return Triangle (Heatmap)

Last updated: Jun 01, 2026

	2011	2012	2013	2014	2015	2016	2017	2018	2019	2020	2021	2022	2023	2024	2025
2011	3.9%	17.4%	25.3%	29.4%	25.7%	18.3%	21.4%	15.7%	17.2%	20.1%	15.6%	11.1%	11.0%	10.2%	11.6%
2012		32.7%	37.6%	39.2%	31.8%	21.3%	24.6%	17.5%	19.0%	22.0%	16.9%	11.8%	11.6%	10.7%	12.1%
2013			42.7%	42.6%	31.5%	18.7%	23.1%	15.1%	17.2%	20.7%	15.2%	9.9%	9.9%	9.0%	10.7%
2014				42.5%	26.2%	11.6%	18.6%	10.2%	13.4%	17.9%	12.2%	6.8%	7.1%	6.4%	8.4%
2015					11.8%	-1.2%	11.6%	3.4%	8.3%	14.2%	8.4%	3.0%	3.7%	3.3%	5.7%
2016						-12.7%	11.5%	0.7%	7.5%	14.7%	7.9%	1.8%	2.7%	2.4%	5.1%
2017							42.4%	8.2%	15.2%	22.8%	12.6%	4.5%	5.2%	4.5%	7.3%
2018								-17.7%	3.6%	16.9%	6.1%	-1.8%	0.0%	0.0%	3.6%
2019									30.5%	39.3%	15.5%	2.6%	4.0%	3.3%	7.1%
2020										48.7%	8.7%	-5.3%	-1.8%	-1.5%	3.6%
2021											-20.6%	-24.4%	-14.5%	-11.1%	-3.6%
2022												-28.1%	-11.3%	-7.7%	1.2%
2023													9.5%	4.6%	13.3%
2024														-0.2%	15.3%
2025															33.2%

Distributions

*by ETF Portfolio Weight Last updated: Jun 01, 2026

Profit Margin Distribution

< 0%

64%

1y 3y N/A N/A

0 - 5%

1y 3y N/A N/A

5 - 10%

1y 3y N/A N/A

10 - 15%

1y 3y N/A N/A

15 - 20%

1y 3y N/A N/A

20 - 30%

1y 3y N/A N/A

30 - 40%

1y 3y N/A N/A

> 40%

1y 3y N/A N/A

P/E Ratio Distribution

< 0

73%

1y 3y N/A N/A

0 - 10

1y 3y N/A N/A

10 - 15

1y 3y N/A N/A

15 - 20

1y 3y N/A N/A

20 - 25

1y 3y N/A N/A

25 - 35

1y 3y N/A N/A

35 - 50

1y 3y N/A N/A

> 50

1y 3y N/A N/A

Discounted Cash Flow

Weighted Average Undervaluation

N/A

Undervalued

> 60%

1y 3y N/A N/A

45 - 60%

1y 3y N/A N/A

30 - 45%

1y 3y N/A N/A

15 - 30%

1y 3y N/A N/A

Fair (±15%)

1y 3y N/A N/A

Overvalued

15 - 30%

1y 3y N/A N/A

30 - 45%

1y 3y N/A N/A

45 - 60%

1y 3y N/A N/A

> 60%

1y 3y N/A N/A

Market Cap Size Distribution

Micro Cap

3.2%

1y 3y N/A N/A

Small Cap

20.2%

1y 3y N/A N/A

Mid Cap

46.7%

1y 3y N/A N/A

Large Cap

28.6%

1y 3y N/A N/A

Mega Cap

1.3%

1y 3y N/A N/A

Micro: < $300M Small: $300M–$2B Mid: $2B–$10B Large: $10B–$200B Mega: > $200B

Average metrics of all companies in portfolio

Last updated: Jun 07, 2026

Market
Average

Market Cap The market value of the company. It's calculated by multiplying the share price by the number of outstanding shares.	$30.9B	-
Dividend Yield Yearly payout to shareholders per share. The percentage indicates the payout in relation to the share price.	0.22%	2.03%
Beta Indicates the relationship between the price performance of a share and the market.	0.83	-
P/E Ratio Ratio between share price and earnings per share. A low ratio could indicate that the stock is undervalued or investors aren't expecting high growth. A high ratio could indicate that the stock is overvalued or investors are expecting high growth.	34.02	27.97
Negative P/E Ratio a negative P/E ratio shows that the company is not profitable, and it shows how many years it would take the company to lose its entire market capitalisation if it did not change anything	-31.45	-
Profitable Companies	41%	-
PEG The ratio between the P/E ratio and the growth rate of the company's earnings per share in the last twelve months. A lower PEG could mean that a stock is undervalued.	75.89	15.45
Price to Sales Ratio Market cap divided by the revenue in the most recent year.	14.47	8.31
Price to Book Ratio Price to Book Ratio is the Market cap divided by the Book value of the company	15.43	10.5

Market
Average

Enterprise Value to EBIT Enterprise Value divided by EBIT	-5.88	20.69
Enterprise Value to Revenue Enterprise value divided by revenue	522.39	8.08
Total Debt to Enterprise Value Total debt divided by enterprise value	0.08	0.04
Debt to Equity A higher ratio indicates a higher risk. However, the ratio is difficult to compare between industries where common amounts of debt vary.	-	0.27
Profit Margin Net income divided by revenue of the last 4 quarters. It indicates the company's profitability.	-10318.06%	21.02%
Quarterly Earnings Growth (YoY) The rate at which the company's net income has increased to the same quarter one year ago.	-	-114.4%
Return on Equity Equity divided by market cap.	-34.32%	3.05%
Return on Assets Indicates a company's profitability in relation to its total assets.	6.48%	4.31%
Return on Invested Capital Return on invested capital (ROIC) is net income after dividends divided by the sum of debt and equity. It shows how effective a company is at turning capital invested by shareholders and other debtholders into profits.	-75.09%	3.97%

Sectors

Manufacturing	68.0%
Professional, Scientific, and Technical Services	15.6%
Health Care and Social Assistance	4.2%
Healthcare	1.1%
Basic Materials	0.2%
Other	10.9%

Countries

United States	97.4%
Switzerland	1.3%
United Kingdom	1.1%
Other	0.2%

Limit holdings to companies in a single sector.

$0B >$1T

Ratio between share price and earnings per share. A low ratio could indicate undervaluation.

<0 >50

Ratio of dividends in the last 12 months to current share price.

0% 3%

Revenue increase compared to the same quarter one year ago.

0% 30%

Net income increase compared to the same quarter one year ago.

0% 30%

Profitability of the last quarter.

<-30% >30%

A higher ratio indicates a higher risk. The ratio is difficult to compare between industries.

<0 >3

Discounted cash flow valuation vs. current price. Positive = undervalued, negative = overvalued.

<-50% >+100%

Market Cap

P/E Ratio

Total Investment

Weight

Apellis Pharmaceuticals Inc

APLS - Manufacturing

Market Cap $5.25B

P/E Ratio 38.8

Dividends 0.0%

Total Investment $136.4M

Weight 1.83%

Loading details…

Madrigal Pharmaceuticals Inc

MDGL - Manufacturing

Market Cap $11.23B

P/E Ratio -45.7

Dividends 0.0%

Total Investment $102.81M

Weight 1.38%

Loading details…

TG Therapeutics Inc

TGTX - Manufacturing

Market Cap $6.15B

P/E Ratio 12.6

Dividends 0.0%

Total Investment $100.33M

Weight 1.35%

Loading details…

Insmed Inc

INSM - Manufacturing

Market Cap $20.42B

P/E Ratio -17.1

Dividends 0.0%

Total Investment $99.39M

Weight 1.34%

Loading details…

Scholar Rock Holding Corp

SRRK - Professional, Scientific, and Technical Services

Market Cap $5.31B

P/E Ratio -13.8

Dividends 0.0%

Total Investment $96.45M

Weight 1.30%

Loading details…

Apogee Therapeutics Inc.

APGE

Market Cap $5.38B

P/E Ratio -22.1

Dividends 0.0%

Total Investment $95.48M

Weight 1.28%

Loading details…

Protagonist Therapeutics Inc

PTGX - Manufacturing

Market Cap $6.26B

P/E Ratio -55.3

Dividends 0.0%

Total Investment $92.55M

Weight 1.24%

Loading details…

Summit Therapeutics Inc

SMMT

Market Cap $11.45B

P/E Ratio -10.9

Dividends 0.0%

Total Investment $92.27M

Weight 1.24%

Loading details…

United Therapeutics Corp

UTHR - Manufacturing

Market Cap $23.34B

P/E Ratio 18.6

Dividends 0.0%

Total Investment $92.23M

Weight 1.24%

Loading details…

Praxis Precision Medicines Inc

PRAX - Manufacturing

Market Cap $5.37B

P/E Ratio -22.5

Dividends 0.0%

Total Investment $91.91M

Weight 1.24%

Loading details…

Arrowhead Pharmaceuticals Inc.

ARWR - Manufacturing

Market Cap $10.3B

P/E Ratio -34.6

Dividends 0.0%

Total Investment $91.43M

Weight 1.23%

Loading details…

Cogent Biosciences Inc

COGT - Manufacturing

Market Cap $5.3B

P/E Ratio -5.9

Dividends 0.0%

Total Investment $90.38M

Weight 1.22%

Loading details…

BridgeBio Pharma Inc

BBIO - Manufacturing

Market Cap $13.24B

P/E Ratio -18.1

Dividends 0.0%

Total Investment $88.13M

Weight 1.19%

Loading details…

PTC Therapeutics Inc

PTCT - Manufacturing

Market Cap $5.89B

P/E Ratio -31.4

Dividends 0.0%

Total Investment $87.89M

Weight 1.18%

Loading details…

Cytokinetics Inc

CYTK - Manufacturing

Market Cap $8.89B

P/E Ratio -10.6

Dividends 0.0%

Total Investment $87.76M

Weight 1.18%

Loading details…

Alnylam Pharmaceuticals Inc

ALNY - Manufacturing

Market Cap $40.46B

P/E Ratio 69.8

Dividends 0.0%

Total Investment $87.48M

Weight 1.18%

Loading details…

Exelixis Inc

EXEL - Professional, Scientific, and Technical Services

Market Cap $13.25B

P/E Ratio 16.3

Dividends 0.0%

Total Investment $87.03M

Weight 1.17%

Loading details…

Nuvalent Inc - Ordinary Shares - Class A

NUVL - Professional, Scientific, and Technical Services

Market Cap $6.69B

P/E Ratio -15.9

Dividends 0.0%

Total Investment $86.75M

Weight 1.17%

Loading details…

Kymera Therapeutics Inc

KYMR - Manufacturing

Market Cap $6.1B

P/E Ratio -22.9

Dividends 0.0%

Total Investment $86.56M

Weight 1.16%

Loading details…

Natera Inc

NTRA - Health Care and Social Assistance

Market Cap $30.84B

P/E Ratio -134.6

Dividends 0.0%

Total Investment $86.18M

Weight 1.16%

Loading details…

Key Metrics

Compare similar ETFs

Historical Return

Risk & Analysis Metrics

Volatility

Max Drawdown

Sharpe Ratio

Return Triangle (Heatmap)

Distributions

Profit Margin Distribution

P/E Ratio Distribution

Discounted Cash Flow

Market Cap Size Distribution

Portfolio Concentration

Latest News

BioMarin Pharmaceutical (BMRN) Earnings Expected to Grow: What to Know Ahead of Q2 Release

3 Biotech Stocks That Could Be Multibaggers in the Making: July Edition

Big Money Eyes Halozyme for Strong Growth

Average metrics of all companies in portfolio

Sectors

Countries

Stock Screener

Apellis Pharmaceuticals Inc

Apellis Pharmaceuticals Inc

Madrigal Pharmaceuticals Inc

Madrigal Pharmaceuticals Inc

TG Therapeutics Inc

TG Therapeutics Inc

Insmed Inc

Insmed Inc

Scholar Rock Holding Corp

Scholar Rock Holding Corp

Apogee Therapeutics Inc.

Apogee Therapeutics Inc.

Protagonist Therapeutics Inc

Protagonist Therapeutics Inc

Summit Therapeutics Inc

Summit Therapeutics Inc

United Therapeutics Corp

United Therapeutics Corp

Praxis Precision Medicines Inc

Praxis Precision Medicines Inc

Arrowhead Pharmaceuticals Inc.

Arrowhead Pharmaceuticals Inc.

Cogent Biosciences Inc

Cogent Biosciences Inc

BridgeBio Pharma Inc

BridgeBio Pharma Inc

PTC Therapeutics Inc

PTC Therapeutics Inc

Cytokinetics Inc

Cytokinetics Inc

Alnylam Pharmaceuticals Inc

Alnylam Pharmaceuticals Inc

Exelixis Inc

Exelixis Inc

Nuvalent Inc - Ordinary Shares - Class A

Nuvalent Inc - Ordinary Shares - Class A

Kymera Therapeutics Inc

Kymera Therapeutics Inc

Natera Inc

Natera Inc

Cookie Settings